@article{1864,
  keywords = {Behcet Syndrome, Clinical Trials as Topic, Erythema Nodosum, France, Graft vs Host Disease, Humans, Leprosy, lepromatous, Lupus Erythematosus, Discoid, Skin Diseases, Stomatitis, Aphthous, Teratogens, Thalidomide, Treatment Outcome},
  title = {Thalidomide: new preparation.  For well-defined indications.},
  abstract = {<p>(1) Thalidomide is highly teratogenic.  It can also cause irreversible neuropathy. (2) In type II lepra reactions evidence of efficacy at a dose of 400 mg/day is based on a few relatively old comparative trials and above all a review of more than 4,500 cases.  Most patients feel a benefit within 24-48 hours after beginning the treatment, but most also require lengthy treatment at a reduced dose (25-100 mg/day) to avoid relapses. (3) Two placebo-controlled trials involving a total of 130 patients have shown the efficacy of thalidomide in the treatment of severe recurrent aphthous disease. (4) In Jessner-Kanoff disease, a mild condition, the efficacy of thalidomide has been shown in a single placebo-controlled trial. (5) In chronic lupus erythematosus, non comparative trials have shown remission from skin lesions in patients resistant to previous treatments. (6) In the curative treatment of chronic graft-versus-host disease in bone marrow graft recipients, thalidomide has been assessed only in non comparative trials involving a few dozens of patients.</p>},
  year = {1998},
  journal = {Prescrire international},
  volume = {7},
  pages = {131-4},
  month = {1998 Oct},
  issn = {1167-7422},
  language = {eng},
}